Transfusion dependent thalassaemia management sales will strengthen through 2036, anchored by iron chelating drugs at 51.3% of the therapy segment in 2026. The market was valued at USD 11.20 million in 2025 and is expected to reach USD 22.4 million by 2036, creating an incremental opportunity of USD 10.46 million.